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Today there is general awareness of the potential damage to the heart in left-sided (more than in right-
sided) breast cancer radiotherapy (RT). Historical changes in tumor and heart doses are presented here
along with the impact of different RT techniques and volumes. Individual and pharmacological risk fac-
tors are also examined with respect to radiation damage. The biological mechanisms of harm are only
partially understood, such as the radiobiology of heart damage due to the presence of various radiosen-
sitive structures and their topographic heterogeneity. Furthermore, individual variability may expose
patients to higher or lower risks of late cardiac damage or death. Damage mechanisms and radiobiolog-
ical characteristics in heart irradiation are presented in relation to dosimetric and biological parameters.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.Breast cancer is the most common cancer and the leading cause
of cancer death among women worldwide [1].
Breast-conserving therapy (BCT) and whole breast radiation
treatment (RT) for women with early-stage breast cancer have
been shown to be an adequate alternative to radical mastectomy
for both local control of the tumor and for esthetic results [2–4].
Nevertheless, effects on the heart are a potentially signiﬁcant
and serious clinical problem in radiation therapy treatment of early
breast cancer [5].
In the history of breast cancer RT regimens, the range of doses
to the heart has changed due to the development of new tech-
niques, beam energy, target doses, different volumes, and contour-
ing modalities [6].
Cardiac damage is correlated to the heart-absorbed dose and
differs between left- and right-breast radiation therapy. Many
studies report that the mean cardiac dose is greater for left- than
right-breast irradiation [7,8].
Several previous studies have analyzed the relationship be-
tween cardiac dose and mortality and morbidity (clinical and sub-
clinical disorders) risks for heart diseases. Most analyzed clinical
endpoints are deaths from heart disease and radiation-induced
heart disease (RIHD) such as congestive heart failure (CHF) andrada Statale n. 7, Ospedale ‘‘A.
ri@asl.brindisi.it (M. Portaluri).
er CC BY-NC-ND license.myocardial infarction (MI). The latency of RT-associated cardiac
effects ranges from months, for subclinical disorders such as peri-
carditis, to decades, for clinical diseases such as coronary artery
disease (CAD) and MI. The relative risks (RR) of these clinically sig-
niﬁcant cardiac events, revealed by randomized clinical trials with-
out RT vs. RT, are within a range of 1.2–3.5 after RT [9].
Damage to cardiac micro- and macro-vasculature is the patho-
physiological cause of radiation-related heart disease [10].
Although different mathematical models have been used, the
most widely accepted is the Relative Seriality (RS) model used to
evaluate the correlation between adsorbed cardiac dose and car-
diac risk probability of mortality [5,11–13].
Thus, the beneﬁts in terms of local–regional control and overall
survival in patients with early-stage breast cancer after RT must be
evaluated, weighting the potential risk of mortality from cardiac
damage, among irradiated patients [5].History
Ancient History
Until the 1950s, the heart was not exposed to high doses of radi-
ation, since X-ray generators had limited depth-dose capacity [14].
The advent of megavoltage techniques in the 1950s resulted in
higher doses to the heart, with a consequential increase in clinical
cardiac effects, as shown in the 1960s [15].
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cardio-vascular disease (CVD) risk decreased in line with what
would be expected based on the use of new RT techniques [16].
However, the severity of the problem of RT-induced cardiac dis-
ease did not become widely recognized until the 1990s, when ran-
domized trials in early-stage breast cancer proved that adverse
cardiac effects almost completely outweighed the overall survival
beneﬁts achieved with RT [17].
In 1992, Rutqvist et al. showed that the risk of death from ische-
mic heart disease in women who had received left wide tangential
irradiation in a Stockholm radiotherapy trial in the 1970s, was 3.2
times greater (p < 0.05) than the risk in non-irradiated controls
[16].
In 2007, Taylor et al. studied the most common used RT regimes
for chest wall, breast, and/or local regional lymph nodes and inter-
nal mammary nodes (IMN), in various countries from 1950s to
1990s, after collecting information by protocols, trial publications,
textbooks, and discussions with radiation oncologists who had
worked in various countries from 1950 onwards, to estimate the
doses to the heart and coronary arteries. To reconstruct RT tech-
niques used in previous decades, a virtual simulation and com-
puted tomography (CT) based three-dimensional (3D) treatment
planning was used. A number of 40 CT planning scans of female pa-
tients, from the data base of a United Kingdom (UK) RT depart-
ment, were reviewed. The patients lay supine, with a T-bar arm
rest, like the positioning used in previous decades. For each regime,
heart and left anterior descending (LAD) coronary artery mean
doses were calculated using dose–volume histogram (DVH) and
heart and LAD mean biological effective dose (BED) were calcu-
lated using an alpha/beta (a/b) ratio of 2. The mean heart dose
was 0.9–14.0 Gy for tangential ﬁelds on breast or chest wall and
2.7–16.7 Gy for left direct photon on IMN. For all tecniques used
to treat breast or chest wall and/or IMN the LAD dose exceeded
the heart dose. For left tangential irradiation the mean LAD dose
was about 20 Gy, and part of LAD received >50 Gy. For left direct
photon IMN the mean LAD was about 20 Gy. The greatest variabil-
ity in mean doses was due to patients’ anatomy. This study showed
a wide range in cardiac and LAD doses worldwide between 1950s
and 1990s. Moreover, these estimates with the data of Early Breast
Cancer Trialist’ Collaborative Group (EBCTCG) trials were used to
enable the development of cardiac dose response relationships
and to evaluate the eccess risk of death from heart disease after
some past breast cancer RT tecniques [18].
In 2009, in a new paper Taylor et al. calculated mean heart and
LAD doses that could be important for estimating dose–response
relationships for radiation-induced heart disease in women with
breast cancer in Sweden from the 1950s to the 1990s, years in
which several changes and technological developments occurred
in the RT. Clinical indications about fractionations and tumor dose
changed. Tumor dose increased from 19.1 Gy (standard deviation
(SD) 14.5), with fractionation of 3.5–7.0 Gy in the 1950s to
48.6 Gy (SD 2.4) with fractionation of 2.0 Gy in the 1990s. Techno-
logical developments during these 40 years, went from the use of
low-voltage X-rays machines and cobalt-60 in the 1950s and
1960s, to megavoltage machines in the 1990s. Delineation of the
target in the 1970s usually included a larger volume of tissue
(chest wall, breast, and IMN) compared to earlier and later decades.
All these changes affected dose distribution in the target and in the
heart. Cardiac doses were assessed in 358 patients. The Swedish
nationwide cancer register was used to identify women in the
Stockholm area who had received external beam RT for breast can-
cer since 1958. Virtual simulation, computed tomography planning
and manual planning were used to reconstruct RT regimes. Heart
and coronary artery doses were derived for each woman. In spite
of increased target doses in the 1980s–1990s, the mean heart
and LAD dose decreased (from 7.0 to 3.0 Gy for heart and from21.6 to 12.0 Gy for LAD) as regards the 1950s–1970s when, the tar-
get dose was lower and mean heart and LAD doses were higher
(from 5.1 to 10.5 Gy for heart and from 10.2 to 22.2 Gy for LAD).
These dosimetric data in combination with detailed information
on morbidity and mortality from heart disease could provide for
the development of reliable dose–response relationships for sev-
eral cardiac endpoints and several cardiac structures [6].
Another recently published study compared mean heart and
LAD doses in Danish and Swedish women irradiated during the
period 1977–2001. Although in Sweden the mean target dose in-
creased from 38.7 to 46.6 Gy and mean heart and LAD doses de-
creased from 12.0 to 7.3 Gy and from 23.6 to 18.8 Gy,
respectively for the left side, in Denmark mean target doses and
mean LAD doses increased from 40.6 to 53.8 Gy and from 16.4 to
20.9 Gy, respectively but mean heart dose remained around 6 Gy
for left-sided RT. The differences between the two countries were
because while most of Danish women received electron RT with
beams of energy from 9 to 18 MeV and standard tangential pair
RT with photon beam of energies from 4 to 22 MV, most number
of Swedish women received electron RT in only a few cases and
RT energies for standard tangential pair, oblique anterior, and di-
rect anterior ﬁelds were 60cobalt (60Co). These results suggest that
in the Danish population the risk of radiation-induced heart dis-
ease was similar between 1977 and 2001 but could be lower for
the Swedish population. A total of 1018 cases of heart disease were
identiﬁed in irradiated breast cancer patients using the population-
based disease registries in Denmark and Sweden since the mid-
1970 and 1437 irradiated breast cancer patients who did not devel-
op heart disease, were identiﬁed as controls, in order to relate
mean cardiac dose to the risk of developing heart disease. Heart
disease risk for women with mean heart dose of 5 Gy and 5–14
or 15+ Gy increased by 15% and 108%, respectively [19].
Furthermore, analyzing the mean heart dose for each woman,
the risk of heart disease that resulted increased along with the
increased dose and it had been estimated that heart disease risk in-
creased by 4% for each Gy rise in the mean heart dose.Contemporary history
Recent awareness of the potential problem of radiation-induced
heart disease is contributing to reducing heart dose through the
use of new RT regimes, technologies, target deﬁnition changes,
and new dosimetric constraints, but some exposure is often
unavoidable, especially for treatment of left-sided breast cancer.
To quantify the mean heart and LAD doses from contemporary tan-
gential breast or chest wall RT, Taylor et al. analyzed 55 patients
with breast cancer treated at a UK radiotherapy center during
the year 2006 and compared them with Swedish patients treated
in the 1970s and 1990s. For the 50 patients irradiated on the left
site, the overage mean dose was 2.3 Gy to heart and 7.6 Gy to
LAD. From comparison of Swedish regimes of the 1970s and
1990s with current left tangential RT, heart and LAD doses have de-
creased considerably over the last few years (13.3 in 1970s, 4.7 in
1990s and 2.3 in 2006; 31.8 in 1970s, 21.9 in 1990s and 7.6 in
2006, respectively), but part of the heart still receives >20 Gy for
approximately half of the left-side patients. Various factors con-
tributed to cardiac reduction dose, e.g. the shift of the medial ﬁeld
border, the use of higher energy beams (megavoltage rather 60Co)
and CT data for RT planning. These changes occurred in many dif-
ferent countries and the heart dose decreased worldwide. With use
of advanced RT techniques, the heart and LAD doses could continue
to decrease reducing the risk of RIHD [20].
McGale et al., prospectively analyzed the incidence of radiation-
related heart disease in a large population of 34.825 breast cancer
patients who received RT during long period to straddling two
intervals (older and contemporary history) 1976–2006, in
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study suggests that risk of angina, pericarditis, and valvular disease
occurs during the ﬁrst decade after exposure while the risk of myo-
cardial infarction takes places more than 15 years after exposure.
Moreover, the risk for women with ischemic heart disease before
breast cancer diagnosis is higher than for others [21].
At Karolinska University Hospital, Stockholm, for the last
10 years, treatment of all irradiated left-breast cancer patients
has been planned so that the calculated normal tissue complication
probability (NTCP) for long-term cardiac mortality based on the
existing mathematical models does not exceed 1%. This speciﬁc
constraint has reduced the volume of heart receiving high doses
and has probably reduced the dose to the LAD coronary artery, po-
tential relevant cardiac subunit to the risk of radiation-induced
heart disease. The heart and LAD mean doses evaluated in 2008
for patients irradiated for stage I and II left breast cancer are
decreasing to about 2.8 and 3.3 Gy, respectively (prescribed dose:
46 Gy, 2 Gy/fraction) [6].
Recently, the use of respiratory-gated RT leads to a statistically
signiﬁcant reduction of the NTCPs for the heart. The results of a re-
cent Lithuanian study that compared a respiratory-gated group of
patients with a control group receiving standard radiation therapy
proved that NTCP was reduced in comparison with the control
group by 83% (P < 0.00001) for cardiac mortality [22].
The latest techniques such as forward-planned intensity modu-
lated radiotherapy (for-IMRT), inverse-planned IMRT (inv-IMRT),
helical tomotherapy (HT), and topotherapy compared each other
with three-dimensional conformal radiotherapy (3DCRT), and pro-
duced different dose distributions to the normal tissue. Schubert
et al. compared the plans for each technique to evaluate normal
tissue dose for left-side breast irradiation. HT had the lowest heart
maximum doses (p = 0.020; Dmax (Gy) 33.9 ± 7.7), but resulted in
higher heart mean doses compared to for-IMRT, inv-IMRT, and
topotherapy (p = 0.039; Dmean (Gy) 3.9 ± 1.3). HT reduced heart
V20Gy compared with 3DCRT and for-IMRT, but had higher heart
V5Gy compared to inv-IMRT and topotherapy (p = 0.039; V5Gy (%)
26.5 ± 18.4) [23,24].
Caudell et al., compared dose distribution using three tech-
niques: electronic tissue compensation (ECOMP), inverse-planned
dynamic multileaf collimation (DLMC) IMRT, and tomotherapy
(TOMO). They showed that ECOMP produced superior dose distri-
bution in both the clinical target volume (CTV) and normal tissue
(heart, lung, and controlateral breast) when compared with TOMO
and DMLC plans [25].
Partial breast irradiation (PBI), as a new clinical indication, by
the irradiation of smaller breast volumes can reduce doses to the
heart as Lettmaier et al. have shown. In this study they have at-
tempted a dosimetric comparison between accelerated partial
breast irradiation by means of multicatheter brachytherapy and
conventional whole breast (WB) external beam RT by looking at
differences in risk organ exposure to radiation. In the case of heart,
the D0.1cc (which represents the dose received by the most highly
exposed 0.1 cc of the risk organ, i.e. the dose peak) was only
12.59 Gy for PBI while for external beam whole breast irradiation
was 45.60 Gy. V10 and V5, which measure the volume of heart ex-
posed to relatively low doses of radiation, were for brachytherapy
about a quarter and a half of theWBRT value, respectively (64.11 cc
vs. 242.05 cc for V10 and 208.89 cc vs. 416.00 cc for V5) [26].
The use of new RT techniques showed good target dose homo-
geneity and a different dose distribution to organs at risk (OARs).
Hot spots decreased but heart volume encompassed by lower
doses was increased [27,10]. Probably, at lower doses, the typical
latency period of cardiac damage is much longer (possibly more
than a decade), but the nature and magnitude of the risk following
lower doses is not well characterized and it is not yet clear whether
there is a threshold dose below which there is no risk [28].Left-side vs. right-side breast cancer radiotherapy: heart
consequences
In 2007, Taylor et al. compared whole heart doses for left-sided
vs. right-sided breast cancer, studying dose estimates for breast
cancer RT regimens used worldwide from the 1950s to the
1990s, years in which considerable variations in cardiac doses in
different techniques were evaluated. Heart doses for left-sided
were higher than those of right-sided treatment in breast or chest
wall RT and was 3–17 Gy for left-sided and 2–10 Gy for right-sided
in internal mammary chain RT [18].
Breast RT as practiced in the 1970s and 1980s resulted in signif-
icant myocardial exposure and this was higher when the left breast
was treated. It has been proposed that this difference might result
in greater cardiovascular mortality following irradiation of the left
breast when compared with the right [7].
Swedish cancer registry studies, during the period from 1970–
1985, showed increased mortality due to myocardial infarction
for patients treated for left- compared with right-sided tumors
[29].
Recently, a French Radiation Epidemiology Group – CESP –
investigated long-term cardiovascular mortality for 4456 women
with breast cancer who underwent RT, who survived at least
5 years after treatment at the Institute Gustave Roussy between
1954 and 1984 and were followed up for mortality until the end
of 2003, for over 28 years on average. This study conﬁrmed that
RT, as delivered until the mid-1980s, increased the long-term risk
of death from cardiovascular disease in women treated for the left-
sided breast cancer with contemporary tangential breast or chest
wall RT. This risk may increase with a longer follow-up, even
20 years after RT [30].
Giordano et al. calculated ischemic heart disease mortality after
adjuvant breast RT to be 15 years, comparing women diagnosed
during 1973–1979, 1980–1984, and 1985–1989 in order to esti-
mate whether the risk of cardiac mortality decreased over time.
The results of this study showed for women diagnosed in 1973–
1979, there was a statistically signiﬁcant difference in 15 years
mortality from ischemic heart disease between patients with
left-sided and those with right-sided treatment (13.1% vs. 10.2%);
no difference was found for women diagnosed in 1980–1984
(9.4% vs. 8.7%) or 1985–1989 (5.8% vs. 5.2%). After 1979 the hazard
of death from ischemic heart disease for women with left-sided
versus right-sided treatment declined by 6% [31].
From US Surveillance Epidemiology and End Results (SEER) can-
cer registries, during 1973–2001, women with early breast cancer
of known laterality (left-sided or right-sided) were analyzed and
followed prospectively for cause-speciﬁc mortality until Jan 1,
2002 (Fig. 1).
Therefore, mortality from heart disease increased among wo-
men with left-sided breast tumors RT-treated compared to wo-
men with right-sided tumors, and this increase was greater
during the second decade after the diagnosis than during the
ﬁrst [32].
Another study carried out in Pennsylvania, examining the long-
term cardiac mortality and morbidity after breast irradiation in pa-
tients treated between 1977 and 1994, concluded that irradiation
to the left breast is not associated with a higher risk of cardiac
death up to 20 years after treatment, but is associated with an in-
creased rate of diagnosis of coronary artery disease and myocardial
infarction compared with right breast treatment [8].
The previously mentioned study of McGale et al. is very impor-
tant because radiation-related risk was studied by comparing wo-
men with left-sided and right-sided tumors. Mortality incidence
ratios, left-sided versus right-sided for acute myocardial infarction
was 1.22 (95% CI 1.06–1.42) and the proportional increase in the
incidence ratio was greatest at 15+ years after irradiation; for
Fig. 1. Left-side vs. right-side breast cancer RT: subsequent cardiac mortality ratios by years from breast cancer diagnosis to cardiac death shared out into period of diagnosis
and radiotherapy status (by Darby et al. [32], with permission from Elseiver).
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incidence ratio was greatest at 0–4 years after irradiation; for peri-
carditis it was 1.61 (1.06–2.43) and for valvular heart disease it
was 1.54 (1.11–1.54) while the proportional increase in the inci-
dence ratio was greatest at 5–9 years after irradiation [21].
In a retrospective study, Seddon et al. evaluated radiation-in-
duced defects in myocardial perfusion and in wall motion by sin-
gle-photon emission-computed tomography (SPECT) imaging in
early breast cancer patients treated with megavoltage irradiation,
comparing two groups of patients with left- and right-breast can-
cer at more than 5 years after RT. This study revealed that left-
breast RT was associated with a signiﬁcantly greater number of
myocardial perfusion abnormalities than RT to the right breast
(71% vs. 17% and 35% vs. 9%, respectively) [33].
Unlike all previous studies, to determine whether new RT tech-
niques are associated with increased risk of cardiac morbidity Patt
et al. analyzed 8603 women with left-sided breast cancer and 7907
with right-sided breast cancer who received adjuvant RT. With a
mean follow-up of 9.5 years (range 0–15 years) there were no sig-
niﬁcant differences between left-sided vs. right-sided breast cancer
patients for ischemic heart disease (9.9% vs. 9.7%), valvular heart
disease (2.9% vs. 2.8%), conduction abnormalities (9.7% vs. 9.6%),
and heart failure (9.7% vs. 9.7%) [34].
Bouchardy et al. analyzed whether RT of inner quadrant tumors
(right and left breast) was associated with an increased cardiovas-
cular mortality risk. In this study, cardiovascular mortality was
compared between the inner-quadrant vs. outer-quadrant tumors.
After a mean follow-up of 7.7 years, patients with left-sided breast
cancer had no excess of cardiovascular mortality compared to pa-
tients with right-sided tumors, while RT of inner-quadrant breast
cancer was associated with an important increase in cardiovascu-
lar mortality, probably linked to higher radiation exposure to the
heart due to the site of the boost [35].
Using quantitative coronary angiography Wang et al., measured
the percentage of stenotic lesions, the mean diameters of each seg-ment of the LAD and the right coronary artery in patients who
underwent RT for left-sided and for right-sided breast cancer.
The median time from RT to coronary angiogram was 4.2 years.
There was no signiﬁcantly difference between the two groups
regarding stenosis, degree of stenosis, and mean vessel diameter
[36].
Recently, Erven et al. investigated the regional cardiac function
using strain rate imaging by tissue Doppler echocardiography in 20
left-sided and 10 right-sided breast cancer patients receiving RT to
the breast or chest wall. Standard echocardiography and strain rate
imaging were performed before RT, immediately after RT, and at
2 months follow-up after RT. Left-sided patients had a reduction
in regional cardiac function post-RT and after 2 months but not
right-sided patients [37].Risk-increasing factors
Epidemiology studies have demonstrated that radiation is an
independent risk factor for death from cardiovascular disease at
>10 years after thoracic RT for breast cancer but evidences suggest
that the risk of RT-associated heart disease may be increased by
baseline patient cardiac risk factors and cardio-toxic chemother-
apy [9,10,32,41].
Some factors may inﬂuence the individual patient’s risk of
developing heart disease, and some of these factors are age, hyper-
tension, diabetes mellitus, total cholesterol, family history of early
MI at age <60 years, smoking, and individual sensitivity to late
heart morbidity [38,39].
Systemic therapies of early breast cancer such as anthracy-
clines, trastuzumab, taxanes, tamoxifen, and letrozole have in-
creased over the last few decades and these may potentiate the
radiation’s effects on the heart [40].
In patients with breast cancer, a multi-institutional study of
P10-year survivors noted that smoking and RT synergistically
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ing/no RT) [41]. A similar synergy was noted between hypertension
and left-sided RT for causing CAD (HR = 11.4 vs. right-sided RT
without hypertension) [8]. The impact of age is unclear, but some
studies comparing age >60 years [42], vs. age <50 or 60 years [41]
showed an association with MI post-RT.
Low high-density lipoprotein (HDL) cholesterol and high low-
density lipoprotein (LDL) cholesterol are CAD risk factors for both
sexes. For women, also elevated very-low-density lipoprotein
(VLDL) triglycerides also seem to be an additional risk factor for
CAD [43], but no studies have analyzed the relationship between
these risk factors and RT for increasing radiation cardio-toxicity.
Few studies have analyzed the role of baseline cardiac risk fac-
tors in increase of heart disease hazard many years after irradiation
in the patients with RT-treated early breast cancer, so further stud-
ies are needed to investigate the consequences of radiation expo-
sure in this large population of patients with long life expectancy.
However, chemotherapy may be an important additional non
patient-identiﬁed RT-associated risk factor. Anthracycline-contain-
ing chemotherapy regimens for treatment of breast cancer are used
routinely. Without RT, anthracyclines are known to have a cumu-
lative dose-dependent risk of dilated cardiomyopathy and CHF,
from 1% to 5% of risk with doses <550 mg/m2 for doxorubicin
and 900 mg/m2 for epirubicin, and a sharp increase in risk thereaf-
ter [44]. Chemo-induced CHF, may be wholly or partially reversible
with medications such as angiotensin-converting enzyme inhibi-
tors or b-blockers [45].
Few prospective studies have addressed the potential synergis-
tic effects of RT and cardio-toxic chemotherapy among breast can-
cer patients. A single-institution retrospective study evaluated
cardio-toxicity, with a 6-year median follow-up, in patients treated
with 10 vs. 5 cycles of doxorubicin (A) (45 mg/m2) and cyclophos-
phamide (C) (500 mg/m2) chemotherapy. The subgroup of patients
treated with synergic RT showed a signiﬁcant increase in cardiac
events among patients receiving 10 cycles of chemotherapy and
RT if compared with estimated baseline cardiovascular risk [46].
Furthermore, an additional risk of congestive heart failure from
RT in combination with non-anthracyclin chemotherapy (cyclo-
phosphamide, methotrexate, and ﬂuorouracil – CMF) has been
indicated (HR = 1.85 vs. RT only) at retrospective study by Hooning
et al. [41].
Harrigan et al. analyzed patients diagnosed with breast cancer
who underwent RT and doxorubicin-containing chemotherapy.
They concluded that radiation doses absorbed by the heart in con-
junction with doxorubicin increased the risk of developing cardiac
damage (ASTRO, 1996).
Trastuzumab combined with chemotherapy improve outcome
in Human Epidermal growth factor Receptor 2 (HER2) – positive
breast cancer [47,48].
Belkacèmi et al. showed that patients treated with concurred
radiation therapy and trastuzumab, receiving a weekly and 3-week
schedule, had a left ventricular ejection fraction decrease after RT
of grade P2 in 10% and 6%, respectively [49].
Halyard et al. analyzed 1503 irradiated patients with early
breast cancer and positive receptors HER2. The patients were ran-
domly assigned to different combinations with doxorubicin and
cyclophosphamide, followed by weekly paclitaxel and later by
trastuzumab. RT commenced within 5 weeks after paclitaxel, con-
currently with trastuzumab. After a median follow-up of 3.7 years,
RT with trastuzumab did not increase cardiac events. The cumula-
tive incidence of cardiac events with doxorubicin, cyclophosfa-
mide, paclitaxel and trastuzumab was 2.7 with or without RT.
The short median follow-up time may preclude the evaluation of
long time cardiac toxicities [50].
The aim of a study by Magnè et al. was to evaluate treatment-
related cardiac toxicity in breast cancer patients treated with doxo-rubicin/docetaxel/CMF sequential or in combined regimens, and
RT. In this prospective trial 64 patients with stages II–III breast can-
cer were included. No patient had any cardiovascular history or
echocardiographic (ECG) abnormalities and the RT technique was
the same in all patients. Left ventricular ejection fraction (LVEF)
measurements were obtained at the baseline, during, at the end
of chemotherapy (before CMF regimen administration), at the
end of RT, and subsequently during the follow-up. Median fol-
low-up was 6 years. LVEF drop occurred in 21 patients with a med-
ian decrease of 10% in the post-treatment period. No cardiac event
was reported and all patients preserved normal cardiac function
[51].
A large phase III trial of the aromatase inhibitor letrozole vs.
tamoxifen showed increased cardiac events in the letrozole arm
at a median follow-up of 26 months [52] which persisted in sub-
group analysis at 51 months [53], but no study has addressed the
relationship between hormone therapy (HT) and RT.Damage mechanism
Pathological expressions of RIHD following therapeutic irradia-
tion include acute and delayed pericarditis, pancarditis with both
pericardial and myocardial ﬁbrosis, CAD, and valvular disease.
From a functional point of view, the most signiﬁcant radiation-in-
duced damage appears to be the myocardial, which may result
from decreased coronary artery blood ﬂow, or effect on microvas-
culature with diffuse interstitial ﬁbrosis, which contribute primar-
ily to diastolic dysfunction [54].
The origin of the process that leads to diastolic dysfunction and
heart failure characterized by replacement of myocardial with ﬁ-
brotic tissue is not well understood, but it cannot be explained
by direct radiation damage on myocytes since they are well differ-
entiated and relatively radio-resistant cells [55,56].
Experimental evidence suggests that RIHD is the result of indi-
rect myocytes secondary effect caused by microvascular and mac-
rovascular damage [57,28], differently from the anthracycline-
induced heart failure, where anthracycline is directly toxic to myo-
cytes [54–56,58].
It has been postulated that damage to the microvascular com-
ponent begins with the injury of endothelial cells within heart
blood capillaries. Endothelial damage leads to an acute inﬂamma-
tory reaction and to activation of the coagulation mechanism with
consequently ﬁbrin deposition. The activation of macrophages and
monocytes during the inﬂammatory process results in the contin-
uous secretion of cytokines and growth factors, including Tumor
Necrosis Factor (TNF), Interleukin (IL)-1, IL-6, IL-18, monocytes
chemotactic factor, and later Platelet-Derived Growth Factor
(PDGF) and Transforming Growth Factor (TGF)-b [59]. These early
effects are followed by endothelial cells proliferation and obstruc-
tion of myocardial capillary lumen [60]. In the late phase, vessel lu-
men progressive obstruction and formation of ﬁbrin thrombi and
platelets, like those shown in electron microscopy studies, result
in ischemia and subsequent myocardial cell death [61]. Since myo-
cytes have no ability to divide, these processes lead to replacement
of cardiac tissue by ﬁbrotic tissue. When this process is extensive,
it may lead to CHF [33,59,60,62].
In this context, cytokines and growth factors probably play a
central role in this process and in particular, TGF-b1, TGF-b2, and
TGF-b3 are highly pleiotropic cytokines secreted by all cell types;
TGF-b molecules are proposed to act as cellular switches that
regulate processes such as immune function, proliferation, and
epithelial-mesenchymal transition. TGF-b1 is the isoform most fre-
quently implicated in the ﬁbro-proliferative process, and it appears
to be a key-molecule and a master switch for the general ﬁbrotic
program [58].
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focal loss of alkaline phosphatase activity within irradiated areas
occurring a few weeks after heart irradiation. In these enzyme-
negative zones, vessel endothelium proliferation occurs followed
by capillary loss. Gradually, those initially small foci increase in
size and capillary density decreases, evolving in ischemia, necrosis,
and reparative ﬁbrosis [57,28,63].
In conclusion, experimental studies show that radiation damage
to the capillary network is the most important cause of myocardial
degeneration and this is supported clinically by the previously ci-
ted studies regarding perfusion defects in breast cancer patients
[33].
Moreover, some studies used animal models to test potential
therapeutic strategies to utilize before and after heart irradiation.
Experimentally, tested medicines (Methylprednisolone or Ibupro-
fen [64], Captopril [65], Amifostine [66] and a combination of Pen-
toxifylline and Alpha-Tocopherol [67]) showed some potential
advantage in the prevention of myocardial damage, but their clin-
ical usefulness has to be yet demonstrated.
Although microvascular injury is a major underlying cause of
radiation-induced myocardial damage, radiation could also dam-
age the major arteries, leading to an accelerated development of
age-related atherosclerosis. The initial event in radiation-induced
atherosclerosis is endothelial cell damage and transmigration of
monocytes into the intima, with subsequent ingestion of low-den-
sity lipoproteins and the formation of fatty streaks [68,69].
Hypercholesterolemia must be present at the time of irradiation
for this to occur, as shown in studies with wild-type mice. In these
studies, lesions occurred only in mice on a high-fat diet at the time
of irradiation and the lesions development could also be inhibited
by the antioxidant CuZn-superoxide dismutase [70].
This suggests that radiation causes an inﬂammatory response
and oxidative damage in large vessels that in combination with
high cholesterol, increases oxidation of low-density lipoproteins
and allows them to be ingested by macrophages, thus triggering
the start of the atherosclerotic process. Once the atherosclerotic
process is initiated, the lipid cells secrete further inﬂammatory
cytokines and growth factors, which stimulate proliferation and
migration of the smooth muscle cell. The atheroma may evolve
to a stable and advanced lesion with a thick protective ﬁbrous
cap or increase in size without developing a protective cap. Exper-
imental studies have shown that radiations not only initiate the
process of atherosclerosis in hypercholesterolemic animals (with
high fat diet or genetically manipulated ApoE/ mice) but also
predispose to the formation of inﬂammatory and atherosclerotic
plaque, with high levels of metalloproteinases and other proteo-
lytic-enzymes, and intra-plaque hemorrhage [71,72].
These large lesions, full of inﬂammatory cells, are ‘‘vulnerable’’.
A lesion may ﬁssure causing thrombosis and reduction of the arte-
rial lumen and it could evolve in the clinical manifestation of radi-
ation-related ischemic CAD: stable angina pectoris, unstable
angina, MI and chronic ischemic heart disease or in some cases
the ruptured lesion may eventually repair itself but leave a stenotic
vessel with a greatly reduced lumen [33,55,56,73–75].
Thus, the pathology and mechanism of coronary artery dam-
age in irradiated patients appear to be similar to those of coro-
nary disease in the general population, although it develops at a
younger age and often in patients without ‘‘classic’’ risk factors
[76].
Stewart et al. [71] tested the efﬁcacy of drugs such as acetylsal-
icylic acid (ASA) and Clopidogrel in this process and concluded that
Clopidogrel inhibited the formation of lesions in non-irradiated
mice but not in irradiated mice. ASA increased plaque stability
but did not reduce the number or size of lesions in irradiated mice
[72]. In conclusion, anti-inﬂammatory and anti-coagulant thera-
pies were less effective at inhibiting radiation-induced atheroscle-rosis than age-related atherosclerosis, suggesting more complex
underlying mechanistic pathways in the irradiated lesions.
In conclusion, from a functional point of view, the most signif-
icant radiation-induced damages appear to be coronary and myo-
cardial ones and it contributes primarily to diastolic dysfunction
[54].
Damage may also affect myocardial cells involved with conduc-
tion, leading to arrhythmias [61].
Injury to the pericardium may present as excessive pericardial
ﬂuid effusion, extensive ﬁbrotic thickening, pericardial adhesions,
and ﬁnally pericarditis [61].
Valve damage usually presents as thickening, ﬁbrosis, and calci-
ﬁcation of the cusp and/or leaﬂets of valves. The pathogenesis of
this process is poorly understood and at present there is a lack of
direct experimental proof. Its very long latency period, exceeding
20 years, may suggest that the mechanism of these sequelae is dif-
ferent from that of other cardiac complications [78]. Valvular
abnormalities may also be related to myocardial ﬁbrosis adjacent
to valve rings, a process leading to their distortion and functional
impairment [61]. It is important to notice that radiation-induced
valvular disease cannot be explained directly by microvascular
damage, since valves do not have blood vessels [77].
Finally the comprehension of biochemical and cellular mecha-
nisms of RIHD needs further study: the current European cardio-
vascular radiation risk research project (CARDIORISK) aims to
investigate these mechanisms causing cardiovascular radiation
risk. In the CARDIORISK project high precision local irradiation of
the hearts with low (0.2 Gy), intermediate (2 Gy) and high (12–
20 Gy) radiation doses is performed in Amsterdam and Dresden
in C57Black mice and in Apo-E mice, with a follow-up for up to
18 months after the irradiation [79].Radiobiology
The radiobiology of heart damage is not well understood due to
the presence of various radiosensitive structures and their topo-
graphic heterogeneity: limited data exist regarding the relation-
ship of damage to particular structures within the heart and
clinical presentation [54]. Moreover, the anatomy of the great ves-
sels as they intersect the heart, and the interaction of the various
structures such as the ventricles and valves is complex. Accord-
ingly, delineation of the clinically relevant sub-regions of the heart
on CT without contrast enhancement is imprecise, and no imaging
modality clearly shows these structures. Newer imaging tools, such
as magnetic resonance imaging, may be able to better identify car-
diac sub-regions, but their application to RT planning is still lim-
ited [80]. Many uncertainties remain regarding which region of
the heart is functionally most important for RT-induced toxicity.
It is not yet known whether a relatively high radiation dose to a
small volume, (e.g. the apex of the heart), or the much lower aver-
age dose to the whole heart is responsible for cardiovascular effects
but the risk of cardiac events in early RT-treated breast cancer pa-
tients is probably related to both dose and irradiated heart volume.
3D treatment planning is a very important tool for correlating
quantitatively the dose/volume with clinical outcomes [77].
In 1991, investigators pooled their clinical experience and infor-
mation regarding partial organ tolerance doses and produced the
‘‘Emami paper’’. Pericarditis was chosen as an endpoint because
of its prevalence and its clinical importance. Total dose (TD)
(Gy) 50/5 for partial and whole organ heart complications is mostly
speculative and the doses of 70 (for 1/3 of the heart volume), 55
(for 2/3 of the heart volume), and 50 for whole organ radiation
are from information in the literature, as well as extrapolation
from the clinical impressions of the clinicians involved in this
agreement. While ‘‘Emami’’ was often criticized for the paper that
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tions, it is widely admired for addressing a clinical need such as
guidelines to help physicians predict the relative safety of pro-
posed treatment plans [81].
Modern treatment techniques have reﬂected efforts to reduce
the heart volume included in the treatment volume. Nevertheless,
it is difﬁcult to avoid cardiac irradiation completely, and a segment
of the LAD coronary artery within the treatment volume is fre-
quently included [20,27,82].
During the last 18 years, few studies have reported associations
between dosimetric parameters and heart outcomes. Various mod-
els have been used to estimate the heart complication risk, and
typically they are based on DVHs. However, DVHs are not ideal
representations of 3D doses as they exclude all heart spatial
information (assuming that all regions are of equal functional
importance) and often do not consider fraction size variations.
RT-induced heart responses are fractionation size dependent, so
this variable is considered by making adjustments for fraction size
based on the linear quadratic (LQ) model [83].
Furthermore, a/b ratios are uncertain. For the whole heart
2.5 Gy is estimated, whereas for coronary vessels it has not been
reliably estimated [61].
The simplest models for estimating risks use metrics such as the
heart maximum or mean dose, while mathematical models are
used to predict the probability of radiation-induced cardiac toxic-
ity, and some of these are now routinely available on RT treatment
planning systems; the most widely used parametric models for
radiation-induced cardiac toxicity are the Lyman–Kutcher–Bur-
man (LKB) model [11], the NTCP model, the so-called RS model
[5,12], and generalized equivalent uniform dose (gEUD) [13].
The connection between radiation dose and radiation effect in a
heart volume may be described by dose–response relationships,
which express the probability of a certain effect (e.g. breast tumor
control and heart damage). NTCP models are usually based on the
concept of functional subunits and of their organization within the
organ. The general assumption of the NTCP model is that the whole
heart volume has a homogeneous radio-sensitivity; strictly speak-
ing this is obviously incorrect as the ventricle and the atrium con-
tain a circulating blood volume of about 30–40% of the whole heart
volume. Parameters evaluated in the RS model, were carried out on
few cardiac deaths and revealed that the dose (Gy) leading to 50%
of complication probabilities (D50) was 52.3 (3.3,+4.7) for the
heart and 52.2 (3.4,+4.7) for the myocardium [27,54].
More recently, the literature has been reviewed to identify the
main clinical and dose-volume predictors for late radiation-in-
duced heart disease [84].
The main clinical endpoints considered were: mortality from
ischemic heart disease and decreased myocardial perfusion. For
these analyses, the volumes considered were either the entire
heart [5], or the left ventricle alone [85].
The Maximum Heart Distance (MHD) is the maximum distance
from the posterior edge of the tangent ﬁeld to the heart contour
and the maximal distance (lmax) of the heart from the hypotenuse
of the right triangle formed by three points (the CT center, top
intersection of the vertical axis with the body contour, and right
side intersection of the horizontal axis with the body contour)
[24,86]. Although a correlation between the NTCP of cardiac mor-
tality and MHD was observed (R2 = 0.808) [87], no clear association
was found between the maximal heart distance and cardiovascular
disease risk [84].
For partial irradiation, conservative (NTCP) model-based esti-
mates predict that a V25Gy < 10% (in 2 Gy per fraction) will be asso-
ciated with a <1% probability of cardiac mortality about 15 years
after RT [84]. Therefore, a conservative model was used to overes-
timate the risk. When applying NTCP models, the user should
know organs at risk deﬁnition, corrections for fractionation, dosecalculation algorithms, and conﬁdence intervals. If NTCP models
for cardiac mortality are used, it should be considered that an NTCP
valueP5% could jeopardize the beneﬁcial effect of RT on survival,
considering that constraints/NTCP values can be used only for
guidance and they must be considered in relation to probability
of tumor control and the speciﬁc patient situation (i.e. lower risk
women, cardiac comorbidity) [9,84].
More narrowly, from the analysis of Pili et al. emerged the dosi-
metric heart constraints to keep the probability of long-term car-
diac mortality <1%. They estimated V30Gy < 20 cm3, V40Gy < 10 cm3,
and V50Gy < 2 cm3 for the dose constraints and D2cm3 < 42 Gy and
D1cm3 < 44 Gy for the volume constraints [24].
Several recent works suggest considering the heart as a serial
organ [24,88,89]. Moreover this high seriality heart behavior is
supported by mathematical analysis but it has yet to be demon-
strated on a physiological basis.
Ultimately the Quantitative Analysis of Normal Tissue Effects in
the Clinic (QUANTEC) summarize the available data to reﬁne the
estimates provided by Emami et al. in a clinically useful manner
[84].Potential tools for early detection of radiation-induced cardiac
damage
In the last years, an increasing number of scientiﬁc studies are
searching for potential markers of individual radiosensitivity,
through studies of anatomical, biochemical, and instrumental
(myocardial echocardiography, scintigraphy, and single-photon
emission computed tomography) parameters correlated to radia-
tion-induced cardiac damage, as they could also be employed in
the early assessment of such heart diseases.
In a comparative study between two breast RT techniques, Pili
et al. analyzed three geometrical and anatomic parameters. The
lmax that indicates howmuch the heart contours were displaced to-
ward the planning target volume (PTV), the angle (a) subtended at
the center of the computed tomography slice by the PTV contour,
and the thorax width/thickness ratio (X/Y). They could provide an
estimate of the cardiac mortality using CT images alone. The geo-
metric parameter, ‘lmax’, together with ‘a’ and ‘X/Y’, were used to at-
tempt the prediction of probability of complications for the heart,
from the CT scan ﬁndings [24].
MHD was proposed as a surrogate for the irradiated heart vol-
ume in the high-dose region in patients treated with tangential
ﬁelds [24,86]. A correlation between MHD and NTCP of cardiac
mortality was observed (R2 = 0.808) [87].
Several studies analyzed the relationship between effects of
chemo-radiation therapy on cardiac biomarkers such as Troponin
I (TnI) and Plasmatic Natriuretic Peptides; Brain Natriuretic Pep-
tide (BNP) seems to be more sensitive and speciﬁc for the detection
of cardiac dysfunction than NT Atrial Natriuretic Peptides (NT-
ANP) in chemotherapy-unrelated heart failure patients [90,91].
Perik et al. measured NT-ANP and BNP after anthracycline che-
motherapy and chest irradiation for breast cancer and concluded
that anticancer therapy initiated an autonomically progressive
process that may ultimately lead to symptomatic cardiac dysfunc-
tion years after treatment, but no clear association was detected
between left-sided chest wall irradiation and higher plasma natri-
uretic peptide concentrations [92]. Although chemotherapy may
contribute to myocardial cell necrosis, in clinical practice it is ex-
tremely difﬁcult to differentiate all possible inﬂuences regarding
cardiac toxicity as demonstrated by Nellessen et al. after the anal-
ysis of TnI and BNP plasma levels in chemo-radio treated patients
[93].
In a retrospective study, D’Errico et al. analyzed the relationship
between N-terminal pro-B-type Natriuretic Peptide (NT-pro BNP)
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with left-sided breast cancer after RT with or without chemother-
apy treatment. They showed increased values of NT-proBNP after
RT when compared with non-irradiated patients, increasing in cor-
relation with high doses in small volumes of the heart and ventri-
cle. Therefore, in this study chemotherapy (in particular with
anthracyclines) did not show a signiﬁcant connection with NT-
proBNP plasma level elevations. The ﬁndings of this study show
that the most important dosimetric parameters are not the mean
doses, but a small percentage of organ volumes (heart or ventricle)
receiving high dose levels, suggesting the notion that the heart be-
haves as a serial organ [89].
New prospective studies are still needed to validate that serum
factors are useful as early bio-markers of cardiac damage.
In a previously mentioned work, Erven et al. studied breast can-
cer patients receiving RT to the breast or chest wall using strain
rate imaging (SRI) by tissue Doppler ECG to investigate the
occurrence of early radiation-induced changes in regional cardiac
function. Regional strain (S) and strain rate (SR) values were ob-
tained. Data were compared to the regional radiation dose. SRI
shows a dose-related regional decrease in myocardial function
after RT, observed signiﬁcantly in segments exposed to more than
3 Gy. It could be a useful tool in the evaluation of modern RT tech-
niques, with respect to cardiac toxicity [37].
As LVEF values decreased in patients with left ventricular dys-
function or coronary artery disease [94,95], Perik et al., in the pre-
viously mentioned study, determined LVEF through radionuclide
ventriculography and natriuretic peptide plasma concentrations
in RT- and chemotherapy (CHT) – treated patients with left breast
cancer. After a median of 2.7 years following chemotherapy and
chest wall irradiation, subnormal LVEF values were observed in
about 13% of the 54 patients examined [92].
Late studies using imaging diagnostic instrumentals showed
microvascular impairment soon after breast cancer RT. In 1998,
Prosnitz et al. began enrolling patients with left-sided breast can-
cer for a prospective study to determine RT effects on heart using
modern techniques. Patients had pre-RT and serial post-RT SPECT,
gated cardiac myocardial perfusion scans, to valuated changes in
heart functions. Perfusion defects were diagnosed in 50–63% of
women 6–24 months after RT. The volume of the left ventricle in
the RT ﬁeld was correlated with the incidence of cardio-toxicity.
With 1–5% of the left ventricle within the tangent ﬁelds, 25% of pa-
tients had perfusion defects and with more than 5% of the left ven-
tricle in the ﬁeld, 55% of patients had perfusion defects [96].
A recent study from the Duke University Medical Center of Dur-
ham, NC used SPECT technique to provide quantitative data on left
ventricular regional myocardial perfusion, regional wall motion,
and ejection fraction (EF). They showed that RT caused regional
cardiac perfusion defects in approximately 40% of 114 patients
with left-sided breast cancer 6–24 months after RT. Such perfusion
defects were prevalent in patients with larger volumes of the left
ventricle (LV) within the RT ﬁelds, even though these volumes
are a relatively small fraction of the myocardium (approximately
5% of the LV), which corresponds to 2–3% of the heart. The study
showed that the incidence of perfusion defects was clearly related
to the volume of the left ventricle included in the radiation ﬁeld:
10–20% compared to 50–60% reduction in perfusion for volumes
<5% and >5%, respectively. The rates of wall-motion defects appear
greater in patients with perfusion abnormalities than in patients
with normal SPECT scans and the location was the anterior por-
tions of LV, which corresponds to the region of the heart within
the RT ﬁeld. Instead, no correlation exists, between the presence
or absence of perfusion defects and the rates of declines in EF of
5% points or more [97].
Seddon et al., compared radiation-induced defects in myocar-
dial perfusion imaging with SPECT in early left vs right breast can-cer patients treated with modern RT technique and concluded that
left-sided breast cancer was associated with a signiﬁcantly greater
number of myocardial perfusion abnormalities than the right-
sided one. These abnormalities were both reversible and irrevers-
ible, suggesting that RT can lead to both myocardial damage and
to epicardial coronary disease. With a minimum of 5 years’ fol-
low-up since treatment, no abnormalities were considered to be
clinically signiﬁcant [33].
Conclusion
Left breast irradiation in patients with early breast cancer in-
volves radiation-induced cardiovascular disease risk. New irradia-
tion techniques permit to reduce heart doses and related cardiac
mortality risk. Nevertheless, in some anatomical conditions heart
doses may be too high yet.
There are evidences that some conditions may be associated
with increased mortality risk as in RT of inner-quadrant breast (left
and right), probably linked to higher cardiac exposition due to the
site of the boost. Some baseline patient cardiac risk factors, such as
age >60 years, hypertension, and smoking, when simultaneously
present to RT, increase the rate of fatal MI. Also, systemic cardio-
toxic therapies administered synergistically to RT show a signiﬁ-
cant increase in cardiac event as compared with estimated baseline
cardiovascular risk.
Althoughmechanisms of biological damage to microvasculature
and macrovasculature are partially understood, the radiobiology of
the heart damage is not well understood due to the presence of
various radiosensitive structures and their topographic heteroge-
neity. Which part of the heart is most radiosensitive and should
be chosen as a reference point for tolerance doses?
It is useful to use NTCP models for cardiac mortality, consider-
ing that constraints/NTCP values should be used only for guidance
and they must be considered in relation to the probability of tumor
control and the speciﬁc patient situations.
The analysis of anatomical parameters and cardiac biomarkers
and echocardiographic data should be correlated with the different
dosimetric constraints in order to identify individual radiosensitiv-
ity and which patients are most at risk for radiation-induced car-
diovascular disease.
Because the main limit of clinical research into radiation-in-
duced cardiovascular risk is the extremely long latency to symp-
tomatic disease, new studies are needed to evaluate which
patients can undergo whole breast radiation treatment after breast
conservation surgery without modifying the overall survival and
quality of life by cardiovascular radiation-induced damage.
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